Snyder C, Metcalfe K, Sopik V, Royer R, Zhang S, Narod S A, Akbari M R, Lynch H T
Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE, USA.
Breast Cancer Res Treat. 2015 Apr;150(3):637-41. doi: 10.1007/s10549-015-3347-x. Epub 2015 Mar 21.
The purpose of this study is to determine the prevalence of PALB2 mutations among breast cancer families from the United States. The PALB2 gene was screened for mutations in 90 familial breast cancer patients from the Creighton University Breast Cancer Family Registry. These patients had previously tested negative for mutations in BRCA1 and BRCA2. Two of 90 breast cancer patients (2.2 %) were found to carry a truncating mutation in PALB2 (c.2411_2412delCT and c.2053delC). Both probands were diagnosed with breast cancer before age 35 and each had three relatives with breast cancer. Mutations in PALB2 are less common than BRCA1 and BRCA2 in familial breast cancer patients. However, testing for PALB2 mutations is a useful adjunct for patients undergoing testing for BRCA1 and BRCA2.
本研究的目的是确定美国乳腺癌家族中PALB2突变的患病率。对来自克里顿大学乳腺癌家族登记处的90例家族性乳腺癌患者的PALB2基因进行了突变筛查。这些患者之前BRCA1和BRCA2突变检测均为阴性。90例乳腺癌患者中有2例(2.2%)被发现携带PALB2截短突变(c.2411_2412delCT和c.2053delC)。两位先证者均在35岁之前被诊断为乳腺癌,且每人都有三位患乳腺癌的亲属。在家族性乳腺癌患者中,PALB2突变比BRCA1和BRCA2突变少见。然而,对PALB2突变进行检测对于接受BRCA1和BRCA2检测的患者是一项有用的辅助检查。